Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT ID: NCT05320198
Last Updated: 2026-01-23
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
150 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-06-06
Study Completion Date
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
NCT00724334
Myelofibrosis
COMPLETED
PHASE1/PHASE2
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
NCT00916227
Myelodysplastic Syndromes
COMPLETED
PHASE1
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
NCT02240706
Myelodysplastic Syndromes
TERMINATED
PHASE2
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867
Myelodysplastic Syndromes
RECRUITING
PHASE2
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
NCT01496495
Myelodysplastic Syndromes
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myelofibrosis; Anemia
Anemia
Myelofibrosis
Myelofibrosis Due to and Following Polycythemia Vera
Primary Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Myelodysplastic Syndromes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1b: Dose Escalation
In the Phase 1b (dose-escalation) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
Group Type
EXPERIMENTAL
DISC-0974
Intervention Type
DRUG
DISC-0974 is administered subcutaneously.
Phase 2: Expansion
In the Phase 2 (expansion) portion of the study, DISC-0974 will be administered subcutaneously every 4 weeks.
Group Type
EXPERIMENTAL
DISC-0974
Intervention Type
DRUG
DISC-0974 is administered subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DISC-0974
DISC-0974 is administered subcutaneously.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants are eligible for the study if all of the following criteria apply:
1. Age 18 years or older at the time of signing the informed consent form (ICF).
2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.55
For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.
3. Washout of at least 28 days prior to Screening of the following treatments:
1. Androgens
2. EPO
3. Cladribine
4. Immunomodulators (lenalidomide, thalidomide)
5. Luspatercept/sotatercept
6. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.
Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.
4. Anemia:
For Phase 1b: Hgb \<10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb \<10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.
For Phase 2:
TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening nTD cohort: Non-transfusion dependence, baseline Hgb \<10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion
5. Stable dosing of MF-directed therapy:
1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.
2. Interferon alpha stable dosing for at least 12 weeks prior to Screening.
3. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD high, TD low, and nTD cohorts, JAK inhibitors allowed include momelotinib, pacritinib, fedratinib, and ruxolitinib.
4. If the participant discontinues JAK inhibitor (including momelotinib/pacritinib/ruxolitinib/fedratinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.
6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.
7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.
8. TSAT \<75% (local lab acceptable).
9. Liver iron concentration by MRI \<7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.
10. Serum ferritin ≥50 µg/L at Screening.
11. Platelet count ≥25,000/µL and \<1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count \<50,000/µL at Screening.
12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.
13. Aspartate aminotransferase (AST) and ALT \<3x upper limit of normal (ULN) at Screening.
14. Direct bilirubin \<2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.
15. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:
1. Stable hormonal contraceptive (≥3 months; female partner)
2. Intrauterine device in place for at least 3 months (female partner)
3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
4. Confirmed successful vasectomy
16. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \>40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:
1. Stable hormonal contraceptive (≥3 months)
2. Intrauterine device in place for at least 3 months
3. Tubal ligation or single male partner with vasectomy
17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).
18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.
19. Able to comply with all study procedures.
Participants are eligible for the MDS exploratory cohort if all of the following criteria apply:
1. Age 18 years or older at the time of signing the ICF.
2. Molecular International Prognostic Scoring System (IPSS-M) classification of very low, low, or intermediate (ie, lower risk) MDS-ringed sideroblasts (RS) negative, MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), or Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN-U) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.
3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:
1. Androgens
2. EPO-stimulating agents
3. Luspatercept
4. Sotatercept (ACE-011)
5. Imetelstat
6. Granulocyte colony-stimulating factor (G-CSF) OR granulocyte-macrophage CSF (GM-CSF)
7. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.
4. Anemia:
1. Baseline Hgb of \<10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb \<10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening
2. Medical history of ≤24 units of PRBC for MDS and anemia
5. ECOG performance score ≤2
6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening
7. TSAT \<75% (local lab acceptable)
8. Liver iron concentration by MRI \<7 mg/g dry weight within 3 months of eligibility confirmation by central review
9. Serum ferritin ≥50 μg/L at Screening
10. Platelet count ≥25,000/μL and \<1,000,000/μL, and total WBC count \<50,000/μL at Screening or otherwise approved by Sponsor
11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula
12. AST and ALT \<3x ULN at Screening
13. Direct bilirubin \<2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.
14. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:
1. Stable hormonal contraceptive (≥3 months; female partner)
2. Intrauterine device in place for at least 3 months (female partner)
3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
4. Confirmed successful vasectomy
15. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:
1. Stable hormonal contraceptive (≥3 months)
2. Intrauterine device in place for at least 3 months
3. Tubal ligation or single male partner with vasectomy
16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).
17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.
18. Able to comply with all study procedures.
1. Age 18 years or older at the time of signing the informed consent form (ICF).
2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.55
For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.
3. Washout of at least 28 days prior to Screening of the following treatments:
1. Androgens
2. EPO
3. Cladribine
4. Immunomodulators (lenalidomide, thalidomide)
5. Luspatercept/sotatercept
6. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.
Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.
4. Anemia:
For Phase 1b: Hgb \<10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb \<10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.
For Phase 2:
TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening nTD cohort: Non-transfusion dependence, baseline Hgb \<10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion
5. Stable dosing of MF-directed therapy:
1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.
2. Interferon alpha stable dosing for at least 12 weeks prior to Screening.
3. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD high, TD low, and nTD cohorts, JAK inhibitors allowed include momelotinib, pacritinib, fedratinib, and ruxolitinib.
4. If the participant discontinues JAK inhibitor (including momelotinib/pacritinib/ruxolitinib/fedratinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.
6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.
7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.
8. TSAT \<75% (local lab acceptable).
9. Liver iron concentration by MRI \<7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.
10. Serum ferritin ≥50 µg/L at Screening.
11. Platelet count ≥25,000/µL and \<1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count \<50,000/µL at Screening.
12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.
13. Aspartate aminotransferase (AST) and ALT \<3x upper limit of normal (ULN) at Screening.
14. Direct bilirubin \<2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.
15. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:
1. Stable hormonal contraceptive (≥3 months; female partner)
2. Intrauterine device in place for at least 3 months (female partner)
3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
4. Confirmed successful vasectomy
16. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \>40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:
1. Stable hormonal contraceptive (≥3 months)
2. Intrauterine device in place for at least 3 months
3. Tubal ligation or single male partner with vasectomy
17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).
18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.
19. Able to comply with all study procedures.
Participants are eligible for the MDS exploratory cohort if all of the following criteria apply:
1. Age 18 years or older at the time of signing the ICF.
2. Molecular International Prognostic Scoring System (IPSS-M) classification of very low, low, or intermediate (ie, lower risk) MDS-ringed sideroblasts (RS) negative, MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T), Chronic Myelomonocytic Leukemia (CMML), Atypical Chronic Myeloid Leukemia (aCML), or Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN-U) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.
3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:
1. Androgens
2. EPO-stimulating agents
3. Luspatercept
4. Sotatercept (ACE-011)
5. Imetelstat
6. Granulocyte colony-stimulating factor (G-CSF) OR granulocyte-macrophage CSF (GM-CSF)
7. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.
4. Anemia:
1. Baseline Hgb of \<10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb \<10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening
2. Medical history of ≤24 units of PRBC for MDS and anemia
5. ECOG performance score ≤2
6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening
7. TSAT \<75% (local lab acceptable)
8. Liver iron concentration by MRI \<7 mg/g dry weight within 3 months of eligibility confirmation by central review
9. Serum ferritin ≥50 μg/L at Screening
10. Platelet count ≥25,000/μL and \<1,000,000/μL, and total WBC count \<50,000/μL at Screening or otherwise approved by Sponsor
11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula
12. AST and ALT \<3x ULN at Screening
13. Direct bilirubin \<2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.
14. If male with female sexual partner(s) of childbearing potential, agrees to use 1 of the following highly effective methods of contraception during the study and for at least 8 weeks after the last study drug dose:
1. Stable hormonal contraceptive (≥3 months; female partner)
2. Intrauterine device in place for at least 3 months (female partner)
3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)
4. Confirmed successful vasectomy
15. If female, then EITHER postmenopausal (defined as 12 months of spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy), surgically sterile, OR agreeable to use 1 of the following highly effective contraception methods (listed below) on Day 1 (or earlier) and for at least 8 weeks after the last dose of study drug:
1. Stable hormonal contraceptive (≥3 months)
2. Intrauterine device in place for at least 3 months
3. Tubal ligation or single male partner with vasectomy
16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).
17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.
18. Able to comply with all study procedures.
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical History, Participants with MF and Anemia
1. Hereditary hemochromatosis
2. Hemoglobinopathy or intrinsic RBC defect associated with anemia
3. Total splenectomy
4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression
5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding
6. Active immune-mediated hemolytic anemia
7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening
8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery
9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:
1. basal or squamous cell carcinoma
2. carcinoma in situ of the cervix or the breast
3. histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \[TNM\] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement
10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening
11. Known allergic reaction to any study drug excipient
12. A history of anti-drug antibody formation
13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction \<35%
14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load
15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)
Treatment History, Medical History, Participants with MF and Anemia
16. Iron chelation therapy in the 28 days prior to Screening
17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening
Laboratory Exclusions, Medical History, Participants with MF and Anemia
18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening
19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening
Miscellaneous, Medical History, Participants with MF and Anemia
20. Pregnant or lactating
21. Condition or concomitant medication that would confound the ability to interpret study data
22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study
23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening
Participants are excluded from the MDS exploratory cohort if any of the following criteria apply:
Medical History, Participants with MDS and Anemia
1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases
2. Peripheral blasts ≥5%
3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy
4. Prior treatment with \>3 anemia-directed therapies (unless otherwise approved by Sponsor) including:
1. Luspatercept
2. Sotatercept (ACE-011)
3. EPO-stimulating agent
4. Imetelstat
5. Hereditary hemochromatosis
6. Hemoglobinopathy or intrinsic RBC defect associated with anemia
7. Total splenectomy
8. Hematopoietic cell transplant within the past 10 years
9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding
10. Active immune-mediated hemolytic anemia
11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening
12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery
13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:
1. basal or squamous cell carcinoma
2. carcinoma in situ of the cervix or the breast
3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement
14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening
15. Known allergic reaction to any study drug excipient
16. A history of antidrug antibody formation
17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction \<35%
18. Active hepatitis B or C, or HIV with detectable viral load
19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)
Treatment History, Participants with MDS and Anemia
20. Iron chelation therapy in the 28 days prior to Screening
21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening
Laboratory Exclusions, Participants with MDS and Anemia
22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening
Miscellaneous, Participants with MDS and Anemia
23. Pregnant or lactating
24. Condition or concomitant medication that would confound the ability to interpret study data
25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study
26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening
Medical History, Participants with MF and Anemia
1. Hereditary hemochromatosis
2. Hemoglobinopathy or intrinsic RBC defect associated with anemia
3. Total splenectomy
4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression
5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding
6. Active immune-mediated hemolytic anemia
7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening
8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery
9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:
1. basal or squamous cell carcinoma
2. carcinoma in situ of the cervix or the breast
3. histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \[TNM\] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement
10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening
11. Known allergic reaction to any study drug excipient
12. A history of anti-drug antibody formation
13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction \<35%
14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load
15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)
Treatment History, Medical History, Participants with MF and Anemia
16. Iron chelation therapy in the 28 days prior to Screening
17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening
Laboratory Exclusions, Medical History, Participants with MF and Anemia
18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening
19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening
Miscellaneous, Medical History, Participants with MF and Anemia
20. Pregnant or lactating
21. Condition or concomitant medication that would confound the ability to interpret study data
22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study
23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening
Participants are excluded from the MDS exploratory cohort if any of the following criteria apply:
Medical History, Participants with MDS and Anemia
1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases
2. Peripheral blasts ≥5%
3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy
4. Prior treatment with \>3 anemia-directed therapies (unless otherwise approved by Sponsor) including:
1. Luspatercept
2. Sotatercept (ACE-011)
3. EPO-stimulating agent
4. Imetelstat
5. Hereditary hemochromatosis
6. Hemoglobinopathy or intrinsic RBC defect associated with anemia
7. Total splenectomy
8. Hematopoietic cell transplant within the past 10 years
9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding
10. Active immune-mediated hemolytic anemia
11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening
12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery
13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:
1. basal or squamous cell carcinoma
2. carcinoma in situ of the cervix or the breast
3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement
14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening
15. Known allergic reaction to any study drug excipient
16. A history of antidrug antibody formation
17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction \<35%
18. Active hepatitis B or C, or HIV with detectable viral load
19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)
Treatment History, Participants with MDS and Anemia
20. Iron chelation therapy in the 28 days prior to Screening
21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening
Laboratory Exclusions, Participants with MDS and Anemia
22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening
Miscellaneous, Participants with MDS and Anemia
23. Pregnant or lactating
24. Condition or concomitant medication that would confound the ability to interpret study data
25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study
26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Disc Medicine, Inc
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Will Savage, MD PhD
Role: STUDY_DIRECTOR
Disc Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope - Duarte
Duarte, California, United States
Site Status
RECRUITING
City of Hope - Lennar
Irvine, California, United States
Site Status
RECRUITING
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Site Status
RECRUITING
Sylvester Cancer Center - U Miami
Miami, Florida, United States
Site Status
RECRUITING
Moffitt Cancer Center
Tampa, Florida, United States
Site Status
RECRUITING
Emory Winship Cancer Institute
Atlanta, Georgia, United States
Site Status
RECRUITING
University of Michigan
Ann Arbor, Michigan, United States
Site Status
RECRUITING
Mayo Clinic Rochester
Rochester, Minnesota, United States
Site Status
RECRUITING
Washington University St.Louis
St Louis, Missouri, United States
Site Status
RECRUITING
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site Status
RECRUITING
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site Status
RECRUITING
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
Site Status
RECRUITING
Gabrail Cancer Center Research
Canton, Ohio, United States
Site Status
TERMINATED
Cleveland Clinic
Cleveland, Ohio, United States
Site Status
RECRUITING
Oregon Health and Science University
Portland, Oregon, United States
Site Status
RECRUITING
Sargon Research - Pennsylvania Cancer Specialists and Research Center
Gettysburg, Pennsylvania, United States
Site Status
WITHDRAWN
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site Status
RECRUITING
MD Anderson
Houston, Texas, United States
Site Status
RECRUITING
University of Washington
Seattle, Washington, United States
Site Status
RECRUITING
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DISC-0974-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
NCT00502112
COMPLETED
PHASE1
Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
NCT01749514
COMPLETED
PHASE2
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
NCT00005845
COMPLETED
PHASE1
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
NCT02124746
COMPLETED
PHASE2
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
NCT01969838
COMPLETED
PHASE3
Lenalidomide for Patients With Myelofibrosis (MF)
NCT00352794
COMPLETED
PHASE2
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
NCT04097821
TERMINATED
PHASE1/PHASE2
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
NCT00910858
COMPLETED
PHASE1/PHASE2
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
NCT00003984
WITHDRAWN
PHASE2
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NCT05835011
TERMINATED
PHASE2
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
NCT05178342
TERMINATED
PHASE2
A Safety Study of XL019 in Adults With Myelofibrosis
NCT00522574
TERMINATED
PHASE1
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
NCT06909136
RECRUITING
PHASE1/PHASE2
Study of SB939 in Subjects With Myelofibrosis
NCT01200498
COMPLETED
PHASE2
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
NCT00630994
TERMINATED
PHASE2
Erlotinib Study for Myelodysplastic Syndrome (MDS)
NCT00977548
COMPLETED
PHASE2
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01895842
COMPLETED
PHASE1
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882
ACTIVE_NOT_RECRUITING
PHASE1
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
NCT05568225
TERMINATED
PHASE2
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
NCT02223598
TERMINATED
PHASE1
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
NCT04896112
WITHDRAWN
PHASE1
Managed Access Program for Momelotinib in Myelofibrosis
NCT05582083
NO_LONGER_AVAILABLE
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
NCT00109538
TERMINATED
PHASE3
Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.
NCT01039350
TERMINATED
PHASE2
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
NCT02784496
COMPLETED
PHASE2